Immuron Limited (ASX:IMC) is set to raise $9.66 million via a fully underwritten rights issue at $0.005 per share to fund Phase 2B clinical trials for the treatment of Non-Alcoholic SteatoHepatitis.
Proceed will also be used to continue the global commercialisation of its travel sickness product Travelan, repay debt and fund development and commercialisation of other Immuron products.
Patersons Securities is lead manager and underwriter to the offer, with BBY Limited acting as broker.
Shares will be offered on the basis of 11 new shares priced at $0.005 each for every 6 shares held.
Immuron's first product Travelan is approved, in the marketplace generating sales, with growing revenues.
And the company's proposed treatment for Non-Alcoholic SteatoHepatitis, or fatty liver, is headed towards a $3.2 billion market by 2016 in the US alone, with no current treatment.
Immuron is capitalised at around $12 million, and offers significant potential upside.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.